Abrams JR, Lebwohl MG, Guzzo CA et al. (1999) CTLA4Ig-mediated block- ade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 103:1243–1252. Acha-Orbea H, Mitchell DJ, Timmermann L et al. (1988) Limited heterogene- ity of T cell receptors from lymphocytes mediating autoimmune encepha-lomyelitis allows specifi c immune intervention. Cell 54:263–273. Achiron A, Rotstein Z, Noy S et al. (1996) Intravenous immunoglobulin treat- ment in the prevention of childbirth-associated acute exacerbations in mul-tiple sclerosis: a pilot study. J Neurol 243(1):25–28. Achiron A, Gabbay U, Gilad R et al. (1998) Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses. Neurology 50(2):398–402.
Achiron A, Kishner I, Dolev M et al. (2004a) Effect of intravenous immuno- globu lin treatment on pregnancy and postpartum-related relapses in mul-tiple sclerosis. J Neurol 251:1133–1137.
Achiron A, Kishner I, Sarova-Pinhas I et al. (2004b) Intravenous immunoglo- bu lin treatment following the fi rst demyelinating event suggestive of multiple sclerosis: a randomized, double-blind, placebo-controlled trial. Arch Neurol 61(10):1515–1520.
Achiron A, Lavie G, Kishner I et al. (2004c) T cell vaccination in multiple sclerosis relapsing-remitting nonresponders patients. Clin Immunol 113:155–60. Adamek-Münz VV (1997) Ergotherapie. In: Welter FL, Schönle PVV (Hrsg.): Neurologische Rehabilitation. Stuttgart, Jena, Lübeck: Gustav Fischer.
Agnello D, Bigini P, Villa P et al. (2002) Erythropoietin exerts an anti-infl am- matory effect on the CNS in a model of experimental autoimmune en-cephalomyelitis. Brain Res 952:128–134. Aharoni R, Eilam R, Domev H et al. (2005) The immunomodulator glati- ramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice. Proc Natl Acad Sci USA 102(52):19045–19050. Ahrens N, Salama A, Haas J (2001) Mycophenolate-mofetil in the treatment of refractory multiple sclerosis. J Neurol 248:713–714. Albutt T (1870) On the ophtalmoscopic signs of spinal disease. Lancet 1:76.
Alegre ML, Sattar HA, Herold KC et al. (1994) Prevention of the humoral response induced by an anti-CD3 monoclonal antibody by deoxyspergualin in a murine model. Transplantation 57:1786–1794. Aloisi F, Pujol-Borrell R (2006) Lymphoid neogenesis in chronic infl ammatory Amiry-Moghaddam M, Williamson A, Palomba M et al. (2003) Delayed K+ clearance associated with aquaporin-4 mislocalization: phenotypic defects 2 Literatur
in brains of [alpha]-syntrophin-null mice. Proc Natl Acad Sci USA 100(23):13615–13620. Andersen O, Lycke J, Tollesson PO et al. (1996) Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis. Neurology 47(4):895–900. Ann Marrie R, Rudick RA (2006) Drug Insight: interferon treatment in mul- tiple sclerosis. Nat Clin Pract Neurol 2(1):34–44.
Anonymus (1991) The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. The Canadian Coopera-tive Multiple Sclerosis Study Group. Lancet 337(8739):441–446.
Anonymus (1997) The 5-year risk of MS after optic neuritis. Experience of the optic neuritis treatment trial. Optic Neuritis Study Group. Neurology 49(5):1404–1413.
Arcos-Burgos M, Palacio G, Sanchez JL et al. (1999) Multiple sclerosis: as- sociation to HLA DQalpha in a tropical population. Exp Clin Immuno-genet 16(3):131–138.
Arnason BG, Dayal A, Qu ZX (1996) Mechanisms of action of interferon- beta in multiple sclerosis. Springer Semin Immunopathol 18(1):125–148.
Arnason BGW, Jacobs G, Hanlon M et al. (1999) TNF neutralization in MS – Results of a randomized, placebo controlled multicenter study. Neurol-ogy 53:457–465.
Arnold DL, Campagnolo D, Panitch H et al. (2008) Glatiramer acetate after mitoxantrone induction improves MRI markers of lesion volume and per-manent tissue injury in MS. J Neurol 255:1473–1478.
Arroyo AG, Yang JT, Rayburn H et al. (1996) Differential requirements for alpha4 integrins during fetal and adult hematopoiesis. Cell 85:997–1008.
Ascherio A, Munger KL, Lennette ET et al. (2001a) Epstein-Barr virus anti- bodies and risk of multiple sclerosis: a prospective study. Jama 286(24):3083–3088. Ascherio A, Zhang SM, Hernan MA et al. (2001b) Hepatitis B vaccination and the risk of multiple sclerosis. N Engl J Med 344(5):327–332.
Averbuch-Heller L, Tusa RJ, Fuhry L et al. (1997) A double-blind controlled study of gabapentin and baclofen as treatment for acquired nystagmus. Ann Neurol 41(6):818–825.
Ayers M (2004) Early glial responses in murine models of multiple sclerosis. Babbe H, Roers A, Waisman A et al. (2000) Clonal expansions of CD8(+) T cells dominate the T cell infi ltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J Exp Med 192(3):393–404.
Baecher-Allan C, Hafl er DA (2004) Suppressor T cells in human diseases. J Baker D, Pryce G, Croxford JL et al. (2000) Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 404:84–87.
Bakker J, Metz L (2004) Devic’s neuromyelitis optica treated with intravenous gamma globulin (IVIG). Can J Neurol Sci 31:265–67.
Bakshi R, Thompson AJ, Rocca MA et al. (2008) MRI in multiple sclerosis: current status and future prospects. Lancet Neurol 7:615–625.
Literatur 3
Banwell B, Ghezzi A, Bar-Or A et al. (2007) Multiple sclerosis in children: clinical diagnosis, therapeutic strategies and future directions. Lancet Neu-rol 6(10):887–902.
Barcellos LF, Oksenberg JR, Begovich AB et al. (2003) for the Multiple Scle- rosis Genetics Group. Am J Hum Genet 72:710–716.
Barkhof F, Filippi M, Miller DH et al. (1997) Comparison of MRI criteria at fi rst presentation to predict conversion to clinically defi nite multiple scle-rosis. Brain120 (Pt 11):2059–2069.
Barkhof F (2002) The clinico-radiological paradox in MS revisited. Curr Opin Barnes MP, Bateman DE, Cleland PG et al. (1985) Intravenous methylpred- nisolone for multiple sclerosis in relapse. J Neurol Neurosurg Psychiatry 48(2):157–159.
Barnett MH, Prineas JW (2004) Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann Neurol 55(4):458–68.
Bar-Or A, Antel J, Bodner CA (2006) Antigen-specifi c immunomodulation in multiple sclerosis patients treated with MBP encoding DNA plasmid (BHT-3009) alone or combined with atorvastatin. Neurology 66(5):A62–A62 Supp. Bar-Or A, Vollmer T, Antel J et al. (2007) Induction of antigen-specifi c toler- ance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial. Arch Neurol 64:1407–1415.
Bastianello S, Pozzilli C, D’Andrea F et al. (1994) A controlled trial of mito- xantrone in multiple sclerosis: serial MRI evaluation at one year. Can J Neurol Sci 21(3):266–270.
Bates D, Toyka KV, Wolinsky JS et al. (2005) Disease management in multiple Baumhackl, Mertin J, Kappos L et al. (2001) The European Study on Enzyme Therapy in Multiple Sclerosis (ESEMS). J Neurol 248(Suppl. 2):II/64.
Baumhackl U, Eibl G, Ganzinger U et al.; the Austrian MS Study Committee (2002) Prevalence of Multiple Sclerosis in Austria Results of a Nationwide Survey. Neuroepidemiology 22(5):226–234.
Baumhackl U, Franta C, Retzl J et al. (2003) A controlled trial of tick-borne encephalitis vaccination in patients with multiple sclerosis: clinical, immu-nological and MRI results. Vaccine 21 (Suppl. 1):S56–56.
Bechtold DA, Kapoor R, Smith KJ (2004) Axonal protection using fl ecainide in experimental autoimmune encephalomyelitis. Ann Neurol 55:607–616. Beck CA, Metz LM, Svenson LW et al. (2005) Regional variation of multiple sclerosis prevalence in Canada. Mult Scler 11(5):516–519.
Beck J, Rondot P, Catinot L et al. (1988) Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations? Acta Neurol Scand 78:318–323.
Beck RW, Cleary PA, Anderson MM et al. (1992) A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med 326(9):581–588.
4 Literatur
Beck RW, Cleary PA, Trobe JD et al. (1993) The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group. N Engl J Med 329(24):1764–1769.
Beck RW (1995) The optic neuritis treatment trial: three-year follow-up re- sults. Arch Ophthalmol 113(2):136–137.
Beck RW (1997) Clinically defi nite multiple sclerosis following optic neuritis. Beer S, Kesselring J (1994) High prevalence of multiple sclerosis in Switzer- land. Neuroepidemiology 13(1–2):14–18.
Beeton C, Wulff H, Barbaria J et al. (2001) Selective blockade of T lymphocyte K(+) channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis. Proc Natl Acad Sci USA 98:13942–13947. Ben-Nun A, Cohen IR (1981) Vaccination against autoimmune encephalomy- elitis (EAE): attenuated autoimmune T lymphocytes confer resistance to induction of active EAE but not to EAE mediated by the intact T lym-phocyte line. Eur J Immunol 11:949–952. Berg D, Maurer M, Warmuth-Metz M et al. (2000) The correlation between ventricular diameter measured by transcranial sonography and clinical dis-ability and cognitive dysfunction in patients with multiple sclerosis. Arch Neurol 57(9):1289–1292.
Bergamaschi R (2003) Glatiramer acetate treatment in Devic’s neuromyelitis Bergamaschi R, Tonietti S, Franciotta D et al. (2004) Oligoclonal bands in Devic’s neuromyelitis optica and multiple sclerosis: differences in repeated cerebrospinal fl uid examinations. Mult Scler 10(1):2–4.
Berger T, Rubner P, Schautzer F et al. (2003) Antimyelin antibodies as a pre- dictor of clinically defi nite multiple sclerosis after a fi rst demyelinating event. N Engl J Med 349(2):139–145.
Bermel RA, Bakshi R (2006) The measurement and clinical relevance of brain atrophy in multiple sclerosis. Lancet Neurol 5(2):158–170.
Bertolotto A (2004) Neutralizing antibodies to interferon beta: implications for the management of multiple sclerosis. Curr Opin Neurol 17(3):241–246. Bettelli E, Pagany M, Weiner HL et al. (2003) Myelin oligodendrocyte glyco- protein-specifi c T cell receptor transgenic mice develop spontaneous au-toimmune optic neuritis. J Exp Med 197(9):1073–1081. Bettelli E, Baeten D, Jager A et al. (2006) Myelin oligodendrocyte glycopro- tein-specifi c T and B cells cooperate to induce a Devic-like disease in mice. J Clin Invest 116(9):2393–2402. Beutler E (1992) Cladribine (2-chlorodeoxyadenosine). Lancet 340:952– Bever CT, Jr. (1994a) The current status of studies of aminopyridines in pa- tients with multiple sclerosis. Ann Neurol 36(Suppl.):S118–121.
Bever CT, Jr., Young D, Anderson PA et al. (1994b) The effects of 4-aminopy- ridine in multiple sclerosis patients: results of a randomized, placebo-con-trolled, double-blind, concentration- controlled, crossover trial. Neurology 44(6):1054–1059.
Literatur 5
Bielekova B, Goodwin B, Richert N et al. (2000a) Encephalitogenic potential of the myelin basic protein peptide (amino acids 83–99) in multiple sclero-sis: results of a phase II clinical trial with an altered peptide ligand. Nat Med 6(10):1167–1175.
Bielekova B, Lincoln A, McFarland H et al. (2000b) Therapeutic potential of phosphodiesterase-4 and -3 inhibitors in Th1-mediated autoimmune dis-eases. J Immunol 164:1117–1124. Bielekova B, Martin R (2004) Development of biomarkers in multiple sclero- Bielekova B, Richert N, Howard T et al. (2004) Humanized anti-CD25 (da- clizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci USA 101:8705–8708. Bielekova B, Catalfamo M, Reichert-Scrivner S et al. (2006) Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci USA 103:5941–5946.
Bisikirska B, Colgan J, Luban J et al. (2005) TCR stimulation with modifi ed anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. J Clin Invest 115:2904–2913. Birnbaum G, Cree B, Altafullah I et al. (2008) Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis. Neurology 71:1390–1395.
Bitsch A, Schuchardt J, Bunkowski S et al. (2000) Acute axonal injury in multiple sclerosis. Correlation with demyelination and infl ammation. Brain 123 (Pt 6):1174–1183.
Bittner S, Meuth SG, Göbel K et al. (2009) TASK1 modulates infl ammation and neurodegeneration in autoimmune infl ammation of the central nervous system. Brain 132(Pt 9):2501–2516. Bjartmar C, Trapp BD (2001) Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences. Curr Opin Neurol 14(3):271–278.
Black JA, Dib-Hajj S, Baker D et al. (2000) Sensory neuron-specifi c sodium channel SNS is abnormally expressed in the brains of mice with experimen-tal allergic encephalomyelitis and humans with multiple sclerosis. Proc Natl Acad Sci USA 97:11598–11602. Blanco Y, Saiz A, Carreras E et al. Autologous haematopoietic-stem-cell trans- plantation for multiple sclerosis. Lancet Neurol 4(1):54–63.
Boiko A, Vorobeychik G, Paty D et al. (2002) Early onset multiple sclerosis: a longitudinal study. Neurology 59: 1006–1010.
Bolton C, Paul C (1997) MK-801 limits neurovascular dysfunction during experimental allergic encephalomyelitis. J Pharmacol Exp Ther 282:397–402. Boneberg EM, Hartung T (2002) Granulocyte colony-stimulating factor at- tenuates LPS-stimulated IL-1beta release via suppressed processing of proIL-1beta, whereas TNF-alpha release is inhibited on the level of proT-NF-alpha formation. Eur J Immunol 32:1717–1725. Bornstein MB, Miller A, Slagle S et al. (1987) A pilot trial of Cop 1 in exac- erbating-remitting multiple sclerosis. N Engl J Med 317(7):408-414.
6 Literatur
Bornstein MB, Miller A, Slagle S et al. (1991) A placebo-controlled, double- blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis. Neurology 41(4):533–539.
Boskovic R, Wide R, Wolpin J et al. (2005) The reproductive effects of beta interferon therapy in pregnancy: a longitudinal cohort. Neurology 65(6):807–811. Bothwell M (1995) Functional interactions of neurotrophins and neurotrophin receptors. Annu Rev Neurosci 18:223–253. Bourdette DN, Whitham RH, Chou YK et al. (1994) Immunity to TCR pep- tides in multiple sclerosis. I. Successful immunization of patients with syn-thetic V beta 5.2 and V beta 6.1 CDR2 peptides. J Immunol 152:2510–2519. Bowen JD, Petersdorf SH, Richards TL et al. (1998) Phase I study of a human- ized anti-CD11/CD18 monoclonal antibody in multiple sclerosis. Clin Pharmacol Ther 64:339–346. Brex PA, Jenkins R, Fox NC et al. (2000) Detection of ventricular enlargement in patients at the earliest clinical stage of MS. Neurology 54(8):1689–1691.
Brex PA, Ciccarelli O, O’Riordan JI et al. (2002) A longitudinal study of ab- normalities on MRI and disability from multiple sclerosis. N Engl J Med 346(3):158–164.
Brinkmann V, Davis MD, Heise CE et al. (2002) The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 277:21453–21457.
Brok HP, van Meurs M, Blezer E et al. (2002) Prevention of experimental autoimmune encephalomyelitis in common marmosets using an anti-IL-12p40 monoclonal antibody. J Immunol 169:6554–6563. Bronnum-Hansen H, Koch-Henriksen N. Stenager E (2004) Trends in sur- vival and cause of death in Danish patients with multiple sclerosis. Brain 127(Pt 4):844-50. Brück W, Stadelmann C (2005) The spectrum of multiple sclerosis: new lessons from pathology. Curr Opin Neurol 18(3):221–224.
Brundula V, Rewcastle NB, Metz LM et al. (2002) Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclero-sis. Brain 125:1297–1308. Brunmark C, Runstrom A, Ohlsson L et al. (2002) The new orally active im- munoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis. J Neuroim-munol 130:163–172. Brusaferri F, Candelise L (2000) Steroids for multiple sclerosis and optic neu- ritis: a meta-analysis of randomized controlled clinical trials. J Neurol 247(6):435–442.
Budde K, Schmouder RL, Brunkhorst R et al. (2002) First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J Am Soc Nephrol 13:1073–1083. Cabrera-Gomez JA, Quevedo-Sotolongo L, Gonzalez-Quevedo A et al. (2007) Brain magnetic resonance imaging fi ndings in relapsing neuromyelitis op-tica. Mult Scler 13:186.
Literatur 7
Cadavid D, Wolansky LJ, Skurnick J et al. (2009) Effi cacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BE-COME study. Neurology 72:1976–1983.
Calabresi PA, Fields NS, Maloni HW et al. (1998) Phase-1 trial of transform- ing-growth-factor-beta-2 in chronic progressive MS. Neurology 51(1):289–292.
Calabresi PA, Wilterdink JL, Rogg JM (2002) An open-label trial of combina- tion therapy with interferon beta-1a and oral methotrexate in MS. Neuro-logy 58(2):314–317. The CAMMS223 Trial Investigators (2008) Alemtuzumab vs. Interferon Beta- 1a in Early Multiple Sclerosis. N Engl J Med 359:1786–1801.
Campbell IK, O’Donnell K, Lawlor KE et al. (2001) Severe infl ammatory ar- thritis and lymphadenopathy in the absence of TNF. J Clin Invest 107:1519–1527.
Cannella B, Raine CS (1995) The adhesion molecule and cytokine profi le of multiple sclerosis lesions. Ann Neurol 37:424–435.
Carreno BM, Collins M (2002) The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annu Rev Immunol 20:29–53. Castillo J, Milani C, Mendez-Allwood D (2009) Ofatumumab, a second-gen- eration anti-CD20 monoclonal antibody, for the treatment of lymphopro-liferative and autoimmune disorders. Expert Opin Investig Drugs 18:491–500.
Cazzato G, Mesiano T, Antonello R et al. (1995) Double-blind, placebo-con- trolled, randomized, crossover trial of high- dose methylprednisolone in patients with chronic progressive form of multiple sclerosis. Eur Neurol 35(4):193–198.
Celius EG, Vandvik B (2001) Multiple sclerosis in Oslo, Norway: prevalence on 1 January 1995 and incidence over a 25-year period. Eur J Neurol 8(5):463–469.
Cepok S, Zhou D, Srivastava R, Nessler S et al. (2005) Identifi cation of Ep- stein-Barr virus proteins as putative targets of the immune response in multiple sclerosis. J Clin Invest 115(5):1352–1360. Cermelli C, Jacobson S (2000) Viruses and multiple sclerosis. Viral Immunol Chabas D, Green AJ, Waubant E (2006) Pediatric multiple sclerosis. NeuroRx Chang A, Tourtellotte WW, Rudick R et al. (2002) Premyelinating oli- godendrocytes in chronic lesions of multiple sclerosis. N Engl J Med 346(3):165–173.
Charo IF, Ransohoff RM (2006) The many roles of chemokines and chemo- kine receptors in infl ammation. N Engl J Med 354:610–621. Chen BJ, Morris RE, Chao NJ (2000) Graft-versus-host disease prevention by rapamycin: cellular mechanisms. Biol Blood Marrow Transplant 6:529–536. Choffl on M, Juillard C, Juillard P et al. (1992) Tumor necrosis factor alpha production as a possible predictor of relapse in patients with multiple scle-rosis. Eur Cytokine Netw 3:523–531.
8 Literatur
Chunduru SK, Sutherland RM, Stewart GA et al. (1996) Exploitation of the Vbeta8.2 T cell receptor in protection against experimental autoimmune encephalomyelitis using a live vaccinia virus vector. J Immunol 156:4940–4945. Ciric B, Howe CL, Paz Soldan M et al. (2003) Human monoclonal IgM anti- body promotes CNS myelin repair independent of Fc function. Brain Pathol 13:608–616.
Claes C, Greiner W, Uber A (2002) Der EQ-5D (EuroQol) als krankheitsüber- greifendes Index-Instrument. In: Schöffski O, Graf v.d. Schulenburg J-M (Hrsg.) Gesundheitsökonomische Evaluationen. Berlin. S. 25–49.
Clanet M, Radue EW, Kappos L et al. European IFNbeta-1a (Avonex) Dose- Comparison Study Investigators (2002) A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS. Neurology 59(10):1507–1517.
Clements JM, Cossins JA, Wells GM et al. (1997) Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumour necrosis factor-alpha inhibitor. J Neuroimmunol 74(1–2):85–94.
Cohen J (1995) IL-12 deaths: explanation and a puzzle. Science 270:908.
Cohen JA, Fischer JS, Bolibrush DM et al. (2000) Intrarater and interrater reliability of the MS functional composite outcome measure. Neurology 54(4):802–806.
Cohen JA, Cutter GR, Fischer JS et al. (2001) Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial. Arch Neurol 58(6):961–967.
Cohen JA, Cutter GR, Fischer JS et al. (2002) IMPACT Investigators Benefi t of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology 59(5):679–687. Cohen JA, Antel JP (2004) Does interferon beta help in secondary progressive Cohen JA, Barkhof F, Comi G et al. (2010) Oral fi ngolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med (Epub ahead of print).
Coles AJ, Wing MG, Molyneux P et al. (1999) Monoclonal antibody treat- ment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 46:296–304. Columba-Cabezas S, Serafi ni B, Ambrosini E et al. (2002) Induction of mac- rophage-derived chemokine/CCL22 expression in experimental autoim-mune encephalomyelitis and cultured microglia: implications for disease regulation. J Neuroimmunol 130:10–21. Comi G, Filippi M, Barkhof F et al. (2001a) Early Treatment of Multiple Sclerosis Study Group. Effect of early interferon treatment on conversion to defi nite multiple sclerosis: a randomised study. Lancet 357(9268):1576–1582.
Comi G, Filippi M, Wolinsky JS (2001b) European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glati-ramer acetate on magnetic resonance imaging-measured disease activity and Literatur 9
burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol 49(3):290–297. Comi G, Martinelli V, Rodegher M et al. (2009) Effect of glatiramer acetate on conversion to clinically isolated syndrome (PreCISe study): a random-ized, double-blind, placebo-cotnrolled trial. Lancet 374(9700):1503–1511.
Compston A, Coles A (2002) Multiple sclerosis. Lancet 359:1221–1231.
Confavreux C, Saddier P, Grimaud J et al. (1996) Risk of cancer from aza- thioprine therapy in multiple sclerosis: a case-control study. Neurology 46(6):1607–1612.
Confavreux C, Hutchinson M, Hours MM et al. (1998) Rate of pregnancy- related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N Engl J Med 339(5):285–291.
Confavreux C, Vukusic S, Moreau T et al. (2000) Relapses and progression of disability in multiple sclerosis. N Engl J Med 343(20):1430–1408. Confavreux C, Suissa S, Saddier P et al. (2001) Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group. N Engl J Med 344(5):319–326.
Confavreux C, Vukusic S, Adeleine P (2003) Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic pro-cess. Brain 126(Pt 4):770–782.
Cook SD, Cromarty JI, Tapp W et al. (1985) Declining incidence of multiple sclerosis in the Orkney Islands. Neurology 35(4):545–551.
Cook SD, MacDonald J, Tapp W et al. (1988) Multiple sclerosis in the Shet- land Islands: an update. Acta Neurol Scand 77(2):148–151.
Cope AP (1998) Regulation of autoimmunity by proinfl ammatory cytokines. Cottrell DA, Kremenchutzky M, Rice GP et al. (1999) The natural history of multiple sclerosis: a geographically based study. 6. Applications to planning and interpretation of clinical therapeutic trials in primary progressive mul-tiple sclerosis. Brain 122(Pt 4):641.
Craner MJ, Lo AC, Black JA et al. (2003) Abnormal sodium channel distribu- tion in optic nerve axons in a model of infl ammatory demyelination. Brain 126:15521561.
Craner MJ, Damarjian TG, Liu S et al. (2005) Sodium channels contribute to microglia/macrophage activation and function in EAE and MS. Glia 49:220–229. Cree BAC, Lamb S, Morgan K et al. (2005) An open label study of the effects of rituximab in neuromyelitis optica. Neurology 64:1270–1272.
Croxford JL, Triantaphyllopoulos KA, Neve RM et al. (2000) Gene therapy for chronic relapsing experimental allergic encephalomyelitis using cells expressing a novel soluble p75 dimeric TNF receptor. J Immunol 164(5):2776–2781. Cserr HF, DePasquale M, Harling-Berg CJ et al. (1992) Afferent and efferent arms of the humoral immune response to CSF-administered albumins in a rat model with normal blood-brain barrier permeability. J Neuroimmunol 41(2):195–202.
10 Literatur
Cursiefen S, Flachenecker P, Rieckmann P et al. (1999) Mitoxantrone (No- vantron) bei schwerer MS. Eine restrospektive Studie bei 15 Patienten. Nervenarzt 70(8):723–731.
Cutter GR, Baier ML, Rudick RA et al. (1999) Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 122 (Pt 5):871–882.
Cyster JG (2005) Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs. Annu Rev Immunol 23:127–159. Dahl OP, Aarseth JH, Myhr KM (2004) Multiple sclerosis in Nord-Trondelag County, Norway: a prevalence and incidence study. Acta Neurol Scand 109(6):378–384.
Dalton CM, Brex PA, Miszkiel KA (2003) New T2 lesions enable an earlier diagnosis of multiple sclerosis in clinically isolated syndromes. Ann Neurol 53(5):673–676.
De Graaf KL, Berne GP, Herrmann MM et al. (2005) CDR3 sequence prefer- ence of TCRBV8S2+ T cells within the CNS does not refl ect single amino acid dependent avidity expansion. J Neuroimmunol 166(1–2):47–54.
De Keyser J, Zwanikken C, Boon M (1998a). Effects of infl uenza vaccination and infl uenza illness on exacerbations in multiple sclerosis. J Neurol Sci 159(1):51–53.
De Keyser J (1998b) Safety of tetanus vaccination in relapsing-remitting mul- tiple sclerosis. Infection 26(5):319.
Dean G, Bhigjee AI, Bill PL et al. (1994) Multiple sclerosis in black South Africans and Zimbabweans. J Neurol Neurosurg Psychiatry 57(9):1064–1069.
Dello Russo C, Gavrilyuk V, Weinberg G et al. (2003) Peroxisome proliferator- activated receptor gamma thiazolidinedione agonists increase glucose me-tabolism in astrocytes. J Biol Chem 278:5828–5836. DeLorenze GN, Munger KL, Lennette ET et al. (2006) Epstein-Barr virus and multiple sclerosis: evidence of association from a prospective study with long-term follow-up. Arch Neurol 63(6):839–844. de Seze J, Stojkovic T, Ferriby D et al. (2002) Devic’s neuromyelitis optica: clinical, laboratory, MRI and outcome profi le. J Neurol Sci 15;197(1–2):57–61.
de Seze J, Debouverie M, Waucquier N et al. (2007) Primary progressive multiple sclerosis: a comparative study of the diagnostic criteria. Mult Scler 13:622–625.
Deryck O, Ketelaer P, Dubois B (2006) Clinical characteristics and long term prognosis in early onset multiple sclerosis. J Neurol 253:720–723.
Devic E (1894) Subacute myelitis complicated by optic neuritis [French]. Bull Devic E (1895) Acute dorsolumbar myelitis with optic neuritis, autopsy [French]. Congrès Français Médicine 1:434.
Diab A, Deng C, Smith JD et al. (2002) Peroxisome proliferator-activated receptor-gamma agonist 15-deoxy-Delta(12,14)-prostaglandin J(2) amelio-rates experimental autoimmune encephalomyelitis. J Immunol 168:2508–2515.
Literatur 11
Diem R, Hobom M, Maier K (2003) Methylprednisolone increases neuronal apoptosis during autoimmune CNS infl ammation by inhibition of an en-dogenous neuroprotective pathway. J Neurosci 23(18):6993–7000.
Dieterich M, Jahn K (2001) Diagnostik und Therapie von Augenmotilitätsstö- rungen. In: Zettl UK, Mix E (Hrsg.) Multiple Sklerose: kausalorientierte, symptomatische und rehabilitative Therapie. Heidelberg: Springer. S. 121–134.
Dinarello CA, Thompson RC (1991) Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro. Immunol Today 12:404–410.
Dousset V, Brochet B, Deloire MS et al. (2006) MR imaging of relapsing mul- tiple sclerosis patients using ultra-small-particle iron oxide and compared with gadolinium. Am J Neuroradiol 27:1000–1005.
Duda PW, Schmied MC, Cook SL et al. (2000) Glatiramer acetate (Copaxone) induces degenerated, Th2-polarized immune responses in patients with multiple sclerosis. J Clin Invest 105(7):967–976.
Durelli L, Bongioanni MR, Cavallo R et al. (1994) Chronic systemic high-dose recombinant interferon alfa-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis. Neurology 44(3 Pt 1):406–413.
Durelli L, Verdun E, Barbero P et al. (2002) Independent Comparison of In- terferon (INCOMIN) Trial Study Group. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 359(9316):1453–1460.
Dyke HJ, Montana JG (2002) Update on the therapeutic potential of PDE4 inhibitors. Expert Opin Investig Drugs 11:1–13.
Ebers GC, Paty DW (1980) CSF electrophoresis in one thousand patients. Can Ebers GC, Bulman DE, Sadovnick AD et al. (1986) A population-based study of multiple sclerosis in twins. N Engl J Med 315(26):1638–1642.
Ebers GC, Sadovnick AD, Risch NJ (1995) A genetic basis for familial ag- gregation in multiple sclerosis. Canadian Collaborative Study Group. Na-ture 377(6545):150–151.
Edan G, Miller D, Clanet M et al. (1997) Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised mul-ticentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 62(2):112–118. Ehrenreich H, Aust C, Krampe H et al. (2004) Erythropoietin: novel ap- proaches to neuroprotection in human brain disease. Metab Brain Dis 19:195–206.
Ehrenreich H, Fischer B, Norra C et al. (2007) Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis. Brain 130(Pt 10):2577–2588. Elices MJ (2002) BX-471 Berlex. Curr Opin Investig Drugs 3:865–869.
Elliott MJ, Maini RN, Feldmann M et al. (1993). Treatment of rheumatoid arthritis with chimeric monoclonal antibody to tumor necrosis factor alpha. Arthritis Rheum 36:1681–1690.
12 Literatur
Engelhardt B, Briskin MJ (2005) Therapeutic targeting of alpha 4-integrins in chronic infl ammatory diseases: tipping the scales of risk towards benefi t? Eur J Immunol 35:2268–2273.
Engelhardt B, Ransohoff RM (2005) The ins and outs of T-lymphocyte traf- fi cking to the CNS: anatomical sites and molecular mechanisms. Trends Immunol 26(9):485–495.
Erb W (1879) About the concurrence of optic neuritis and subacute myelitis [German]. Arch Psychiatr Nervenkr 18791:146.
Eugster HP, Frei K, Bachmann R et al. (1999) Severity of symptoms and de- myelination in MOG-induced EAE depends on TNFR1. Eur J Immunol 29:626–632.
European Study Group on interferon beta-1b in secondary progressive MS (1998) Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 352(9139):1491–1497.
Falcini F, Trapani S, Ricci L et al. (2006) Sustained improvement of a girl af- fected with Devic’s disease over 2 years of mycophenolate mofetil treat-ment. Rheumatology 45:913.
Farina C, Weber MS, Meinl E et al. (2005) Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action. Lancet Neurol 4(9):567–575.
Farrell R, Heaney D, Giovannoni G (2005) Emerging therapies in multiple sclerosis. Expert Opin Emerg Drugs 10:797–816.
Fassas A, Passweg JR, Anagnostopoulos A et al. (2002) Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study. J Neurol 249:1088–1097.
Fazekas F, Offenbacher H, Fuchs S et al. (1988) Criteria for an increased specifi city of MRI interpretation in elderly subjects with suspected multiple sclerosis. Neurology 38:1822–1825.
Fazekas F, Deisenhammer F, Strasser-Fuchs S (1997) Randomised placebo- controlled trial of monthly intravenous immunoglobulin therapy in relaps-ing-remitting multiple sclerosis. Lancet 349:589–593. Fazekas F, Lublin FD, Li D et al. for the PRIVIG Study Group and the UBC MS/MRI Research Group (2008). Intravenous Immunoglobulin in Relaps-ing-Remitting Multiple Sclerosis: A Dose-finding Trial. Neurology 71(4):265–271. Fernandez O, Fernandez V, Alonso A et al. (2004) DQB1*0602 allele shows a strong association with multiple sclerosis in patients in Malaga, Spain. J Neurol 251(4):440–444.
Ferrante P, Fusi ML, Saresella M et al. (1998) Cytokine production and sur- face marker expression in acute and stable multiple sclerosis: altered IL-12 production and augmented signaling lymphocytic activation molecule (SLAM)-expressing lymphocytes in acute multiple sclerosis. J Immunol 160:1514–1521.
Filippi M, Rovaris M, Rice GP et al. (2000a) The effect of cladribine on T(1) „black hole“ changes in progressive MS. J Neurol Sci 176(1):42–44.
Literatur 13
Filippi M, Rovaris M, Iannucci G et al. (2000b) Whole brain volume changes in patients with progressive MS treated with cladribine. Neurology 55(11):1714–1718.
Filippi M, Rovaris M, Rocca MA et al.; Eurpoean/Canadian Glatiramer Ace- tate Study Group (2001) Glatiramer acetate reduces the proportion of new MS lesions evolving into „black holes“. Neurology 57(4):731–733. Filippi M, Dousset V, McFarland HF et al. (2002) Role of magnetic resonance imaging in the diagnosis and monitoring of multiple sclerosis: consensus report of the White Matter Study Group. J Magn Reson Imaging 15(5):499–504.
Filippi M, Rocca M (2004) MR imaging of Devic’s neuromyelitis optica. Neu- Filippi M, Wolinsky JS, Comi G; CORAL Study Group (2006a) Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in pa-tients with relapsing multiple sclerosis: a multicentre, double-blind, ran-domised, placebo-controlled study. Lancet Neurol 5(3):213–220. Filippi M, Rocca MA, Arnold DL et al. (2006b) EFNS guidelines on the use of neuroimaging in the management of multiple sclerosis. Eur J Neurol 13(4):313–325.
Filippini G, Brusaferri F, Sibley WA et al. (2000) Corticosteroids or ACTH for acute exacerbations in multiple sclerosis. Cochrane Database Syst Rev 2000;(4):CD001331. Filippini G, Munari L, Incorvaia B et al. (2003) Interferons in relapsing remit- ting multiple sclerosis: a systematic review. Lancet 361(9357):545–552. Filley C, Sternberg P, Norenberg M (2005) Neuromyelitis optica in the el- Finucane BT, Terblanche OC (2005) Prolonged duration of anesthesia in a patient with multiple sclerosis following paravertebral block. Can J Anaesth 52:493–497.
Fischer JS, Priore RL, Jacobs LD et al. (2000) Neuropsychological effects of Interferon β-1a in relapsing multiple sclerosis. Ann Neurol 48:885–892.
Flechter S, Vardi J, Pollak L et al. (2002) Comparison of glatiramer acetate (Copaxone) and interferon beta-1b (Betaferon) in multiple sclerosis pa-tients: an open-label 2-year follow-up. J Neurol Sci 197(1–2):51–55.
Fontoura P, Garren H, Steinman L (2005) Antigen-specifi c therapies in multi- ple sclerosis: going beyond proteins and peptides. Int Rev Immunol 24:415–446.
Foster CA, Mechtcheriakova D, Storch MK et al. (2009) FTY720 rescue ther- apy in the dark aouti rat model of experimental autoimmune encephalo-myelitis: expression of central nervous system genes and reversal of blood-brain-barrier damage. Brain Pathol 19(2):254–266. Fox RJ, Ransohoff RM (2004) New directions in MS therapeutics: vehicles of Fox RJ, Bethoux F, Goldman MD et al. (2006) Multiple sclerosis: advances in understanding, diagnosing, and treating the underlying disease. Cleve Clin J Med 73(1):91–102. Francis G, Evans A, Panitch H (1997) MRI resuslts of a phase III trial of oral myelin in relapsing-remitting multiple sclerosis. Ann Neurol 42:467.
14 Literatur
Francis GS, Rice GP, Alsop JC; PRISMS Study Group (2005) Interferon beta- 1a in MS: results following development of neutralizing antibodies in PRISMS. Neurology 65(1):48–55. Frank JA, Richert N, Lewis B et al. (2002) A pilot study of recombinant insu- lin-like growth factor-1 in seven multiple sderosis patients. Mult Scler 8(1):24–29.
Fraser C, Klistorner A, Graham S et al. (2006) Multifocal visual evoked po- tential latency analysis: predicting progression to multiple sclerosis. Arch Neurol 63(6):847–850.
Frauwirth KA, Thompson CB (2002) Activation and inhibition of lymphocytes by costimulation. J Clin Invest 109:295–299. Freedman MS, Patry DG, Grand’Maison F (2004); Canadian MS Working Group Treatment optimization in multiple sclerosis. Can J Neurol Sci 31(2):157–168.
Freedman MS, Francis GS, Sanders EA et al.; Once Weekly Interferon beta- 1alpha for Multiple Sclerosis Study Group; University of British Columbia MS/MRI Research Group (2005a) Randomized study of once-weekly in-terferon beta-1a therapy in relapsing multiple sclerosis: three-year data from the OWIMS study. Mult Scler 11(1):41–45.
Freedman MS, Thompson EJ, Deisenhammer F et al. (2005b) Recommended standard of cerebrospinal fl uid analysis in the diagnosis of multiple sclero-sis: a consensus statement. Arch Neurol 62(6):865–870.
Freeman JA, Langdon DW, Hobart JC et al. (1997) The impact of inpatient rehabilitation on progressive multiple sclerosis. Ann Neurol 42(2):236–244.
Friese MA, Fugger L (2005) Autoreactive CD8+ T cells in multiple sclerosis: a new target for therapy? Brain 128(Pt 8):1747–1763.
Friese MA, Montalban X, Willcox N et al. (2006) The value of animal models for drug development in multiple sclerosis. Brain 129:1940–1952.
Frohman EM, Goodin DS, Calabresi PA et al. (2003) Therapeutics and Tech- nology Assessment Subcommittee of the American Academy of Neurology.
The utility of MRI in suspected MS: report of the Therapeutics and Tech-nology Assessment Subcommittee of the American Academy of Neurology. Neurology 61(5):602–611.
Frohman EM, Brannon K, Racke MK et al. (2004) Mycophenolate mofetil in multiple sclerosis. Clin Neuropharmacol 27:80–83. Frohman EM, Havrdova E, Lublin F et al. (2006a) Most patients with multi- ple sclerosis or a clinically isolated demyelinating syndrome should be treated at the time of diagnosis. Arch Neurol 63(4):614–619. Frohman EM, Racke MK, Raine CS (2006b) Multiple sclerosis – the plaque and its pathogenesis. N Engl J Med 354(9):942–955. Fuhr P, Borggrefe-Chappuis A, Schindler C et al. (2001) Visual and motor evoked potentials in the course of multiple sclerosis. Brain 124(Pt 11):2162–2168.
Fujimoto T, Sakoda S, Fujimura H et al. (1999) Ibudilast, a phosphodiesterase inhibitor, ameliorates experimental autoimmune encephalomyelitis in Dark August rats. J Neuroimmunol 95:35–42.
Literatur 15
Fujino M, Funeshima N, Kitazawa Y et al. (2003) Amelioration of experimen- tal autoimmune encephalomyelitis in Lewis rats by FTY720 treatment. J Pharmacol Exp Ther 305:70–77.
Gaertner S, de Graaf KL, Greve B et al. (2004) Antibodies against glyco- sylated native MOG are elevated in patients with multiple sclerosis. Neurol-ogy 63(12):2381–2383.
Gangopadhyay G, Das S, Sarda P et al. (1999) Clinical profi le of multiple sclerosis in Bengal. Neurology India 47:18.
Gartzen K, Limmroth V, Putzki N (2007) Relapsing neuromyelitis optica re- sponsive to glatiramer acetate treatment. Eur J Neurol 14:12.
Gass A, Radu EW, Filippi M et al. (1999) MRT-follow up bei MS. Eine Richt- linie für die Qualitätssicherung. Rofo Fortschr Geb Rontgenstr Neuen Bild-geb Verfahr 170(6):581–586. Gately MK, Renzetti LM, Magram J et al. (1998) The interleukin-12/inter- leukin-12-receptor system: role in normal and pathologic immune respons-es. Annu Rev Immunol 16:495–521.
Gay FW, Drye TJ, Dick GW et al. (1997) The application of multifactorial cluster analysis in the staging of plaques in early multiple sclerosis. Identi-fi cation and characterization of the primary demyelinating lesion. Brain 120 ( Pt 8):1461–1483.
Gbadamosi J, Buhmann C, Moench A et al. (2001) Failure of ondansetron in treating cerebellar tremor in MS patients – an open-label pilot study. Acta Neurol Scand 104(5):308–311.
Genain CP, Nguyen MH, Letvin NL et al. (1995) Antibody facilitation of multiple sclerosis-like lesions in a nonhuman primate. J Clin Invest 96(6):66–74.
Genc S, Koroglu TF, Genc K (2004) Erythropoietin as a novel neuroprotectant. Restor Neurol Neurosci 22:105–119.
Genc K, Genc S, Baskin H et al. (2006) Semin I. Erythropoietin decreases cytotoxicity and nitric oxide formation induced by infl ammatory stimuli in rat oligodendrocytes. Physiol Res 55:33–38.
Germain RN, Stefanova I (1999) The dynamics of T cell receptor signaling: complex orchestration and the key roles of tempo and cooperation. Annu Rev Immunol 17:467–522.
Geurts JJ, Wolswijk G, Bö L et al. (2003) Altered expression patterns of group I and II metabotropic glutamate receptors in multiple sclerosis. Brain 126(Pt 8):1755–1766. Ghalie RG, Edan G, Laurent M et al. (2002a) Cardiac adverse effects associ- ated with mitoxantrone (Novantrone) therapy in patients with MS. Neurol-ogy 59(6):909–913.
Ghalie RG, Mauch E, Edan G et al. (2002b) A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis. Mult Scler 8(5):441–445. Ghezzi A, Deplano V, Faroni J et al. (1997) Multiple sclerosis in childhood: clinical features of 149 cases. Mult Scler 3:43–46.
Ghezzi A, Bergamaschi R, Martinelli V et al.; Italian Devic’s Study Group (IDESG). (2004) Clinical characteristics, course and prognosis of relapsing Devic’s neuromyelitis optica. J Neurol 251(1):47–52.
16 Literatur
Ghezzi A, Bergamaschi R, Martinelli V et al. (2004) Clinical characteristics, course and prognosis of relapsing Devic’s neuromyelitis optica. J Neurol 251:47–52.
Gilden DH (2005) Infectious causes of multiple sclerosis. Lancet Neurol Gilron I, Booher SL, Rowan JS et al. (2001) Topiramate in trigeminal neural- gia: a randomized, placebo-controlled multiple crossover pilot study. Clin Neuropharmacol 24(2):109–112.
Giovannoni G, Goodman A (2005) Neutralizing anti-IFN-beta antibodies: how much more evidence do we need to use them in practice? Neurology 65(1):6–8. Giovannoni G, Coni G, Cook S et al. (2010) A placebo-controlled trial of cladebrine for relapsing multiple sclerosis. N Engl J Med (Epub ahead of print).
Giuliani F, Fu SA, Metz LM et al. (2005) Effective combination of minocycline and interferon-beta in a model of multiple sclerosis. J Neuroimmunol 165:83–91.
Gobbini MI, Smith ME, Richert ND et al. (1999) Effect of open label pulse cyclophosphamide therapy on MRI measures of disease activity in fi ve pa-tients with refractory relapsing-remitting multiple sclerosis. J Neuroim-munol 99(1):142–149.
Gold R, Hartung HP, Lassmann H (1997) T-cell apoptosis in autoimmune diseases: termination of infl ammation in the nervous system and other sites with specialized immune-defense mechanisms. Trends Neurosci 20(9):399–404.
Gold R, Buttgereit F, Toyka KV (2001) Mechanism of action of glucocortico- steroid hormones: possible implications for therapy of neuroimmunological disorders. J Neuroimmunol 117(1–2):1–8.
Gold R, Linington C (2002) Devic’s disease: bridging the gap between labora- tory and clinic. Brain 125(Pt 7):1425–1427. Gold R, Havrdova E, Kappos L et al. (2006a) Safety of a novel oral single- agent fumarate, BG00012, in patients with relapsing-remitting mutiple sclerosis: results of a phase 2 study. J Neurol 253:144.
Gold R, Linington C, Lassmann H (2006b) Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 129(Pt 8):1953–1971. Gold R, Stangel M, Dalakas MC (2007) Drug Insight: the use of intravenous immunoglobulin in neurology – therapeutic considerations and practical issues. Nat Clin Pract Neurol 3:36–44.
Gold R (2008) Combination therapies in multiple sclerosis. J Neurol 255:S51– Gold R, Hartung HP, Wiendl H et al. (2009) Therapie der Multiplen Sklerose mit monoklonalen Antikörpern. Aktuelle Neurologie 36:334–344.
Goldacre MJ, Abisgold JD, Yeates DG et al. (2006) Risk of multiple sclerosis after head injury: record linkage study. J Neurol Neurosurg Psychiatry 77(3):351–353.
Literatur 17
Gonsette RE, Dubois B (2004) Pixantrone (BBR2778): a new immunosuppres- sant in multiple sclerosis with a low cardiotoxicity. J Neurol Sci 223:81–86.
Gonzalo J, Gonzalez-Garcia A, Kalland T et al. (1993) Linomide, a novel im- munomodulator that prevents death in four models of septic shock. Eur J Immunol 23:2372–2374.
Goodin DS, Frohman EM, Garmany GP et al.; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines (2002) Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 58(2):169–178. Goodin D (2006) Age at disability milestones in multiple sclerosis and history of multiple sclerosis: a unifying concept. Brain 129(Pt 12):e56 (Replik d. Autors: e57). Goodkin DE, Bailly RC, Teetzen ML et al. (1991) The effi cacy of azathioprine in relapsing-remitting multiple sclerosis. Neurology 41(1):20–25.
Goodkin DE, Rudick RA, VanderBrug Medendorp S et al. (1995) Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic pro-gressive multiple sclerosis. Ann Neurol 37(1):30–40.
Goodkin DE, Rudick RA, VanderBrug Medendorp S et al. (1996) Low-dose oral methotrexate in chronic progressive multiple sclerosis: analyses of se-rial MRIs. Neurology 47(5):1153–1157.
Goodkin DE, Kinkel RP, Weinstock-Guttman B et al. (1998) A phase II study of i.v. methylprednisolone in secondary-progressive multiple sclerosis. Neuro logy 51(1):239–245.
Goodkin DE, Shulman M, Winkelhake J et al. (2000) A phase I trial of solu- bilized DR2:MBP84-102 (AG284) in multiple sclerosis. Neurology 54(7):1414–1420.
Gordon EJ, Myers KJ, Dougherty JP et al. (1995) Both anti-CD11a (LFA-1) and anti-CD11b (MAC-1) therapy delay the onset and diminish the sever-ity of experimental autoimmune encephalomyelitis. J Neuroimmunol 62:153–160. Gran B, Tranquill LR, Chen M et al. (2000) Mechanisms of immunomodula- tion by glatiramer acetate. Neurology 55(11):1704–1714.
Grauer O, Offenhausser M, Schmidt J et al. (2001) Glukokorticoidsteroidthe- rapie bei Optikusneuritis und MS. Evidenz aus klinischen Studien und prak-tischen Empfehlungen. Nervenarzt 72(8):577–589. Greene YM, Tariot PN, Wishart H (2000) A 12-week open trial of donepizil hydrochloride in patients with multiple sclerosis and associated cognitive impairments. J Clin Psychopharmacol 20:350–356.
Greter M, Heppner FL, Lemos MP et al. (2005) Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis. Nat Med 11(3):328–334.
Grewal IS, Grewal KD, Wong FS et al. (1996) Local expression of transgene encoded TNF alpha in islets prevents autoimmune diabetes in nonobese diabetic (NOD) mice by preventing the development of auto-reactive islet-specifi c T cells. J Exp Med 184(5):1963–1974.
18 Literatur
Gronlie SA, Myrvoll E, Hansen G et al. (2000) Multiple sclerosis in North Norway, and fi rst appearance in an indigenous population. J Neurol 247(2):129–133.
Grytten N, Glad SB, Aarseth JH et al. (2006) A 50-year follow-up of the in- cidence of multiple sclerosis in Hordaland County, Norway. Neurology 66(2):182–186.
Gusev E, Boiko A, Bikova O et al. (2002) The natural history of early onset multiple sclerosis: comparison of data from Moscow and Vancouver. Clin Neurol Neurosurg 104:203–207.
Haas J (2000). High dose IVIG in the post partum period for prevention of exacerbations in MS. Mult Scler 6 (Suppl. 2):S18–20, S33.
Haas J, Firzlaff M (2005) Twenty-four-month comparison of immunomodula- tory treatments – a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone). Eur J Neu-rol 12(6):425–431.
Haas J, Hug A, Viehover A et al. (2005) Reduced suppressive effect of CD4+CD25high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis. Eur J Immunol 35(11):3343–3352.
Haines JL, Ter-Minassian M, Bazyk A et al. (1996) A complete genomic screen for multiple sclerosis underscores a role for the major histocompatability complex. The Multiple Sclerosis Genetics Group. Nat Genet 13(4):469–471.
Harris JO, Frank JA, Patronas N et al. (1991) Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: implications for clinical trials and natural history. Ann Neurol 29(5):548–555.
Hartung HP, Grossman RI (2001) ADEM: distinct disease or part of the MS Hartung HP, Gonsette P, König N et al. (2002) Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multi-centre trial. Lancet 360(9350):2018–2025.
Hartung HP, Gonsette P, König N et al. (2003) A Phase 3 placebo-controlled, double-blind, randomised, multicentre trial of mitoxantrone in progressive multiple sclerosis. Lancet 360(9350):2018–2025.
Hartung HP (2005) Early treatment and dose optimisation BENEFIT and BEYOND. J Neurol 252 (Suppl. 3):iii44–iii50. Hauser SL, Waubant E, Arnold DL et al. HERMES Trial Group (2008) B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358(7):676–688. Havrdova E, Galetta S, Hutchinson M et al. (2009) Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Effi cacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol 8(3):254–260.
Havrdova E, Zivadinov R, Krasensky J et al. (2009b) Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis. Mult Scler 15(8):965–976. Literatur 19
Hawker K, Frohman E, Racke M (2003) Levetiracetam for phasic spasticity in Multiple sclerosis. Arch Neurol 60:1772–1774.
Hawkins SA, McDonnell GV (1999) Benign multiple sclerosis? Clincical course, long term follow up, and assessment of prognostic factors. J Neurol Neurosurg Psychiatry 67:148–152.
Hein T, Hopfenmüller W (2000) Hochrechnung der Zahl an Multiple Sklero- se erkrankten Patienten in Deutschland. Nervenarzt 71(4):288–294.
Hemmer B, Stüve O, Kieseier B et al. (2005) Immune response to immuno- therapy: the role of neutralising antibodies to interferon beta in the treat-ment of multiple sclerosis. Lancet Neurol 4(7):403–412.
Hemmer B, Nessler S, Zhou D et al. (2006) Immunopathogenesis and immu- notherapy of multiple sclerosis. Nat Clin Pract Neurol 2(4):201–211. Hengartner MO (2001) Apoptosis: corralling the corpses. Cell 104(3):325– Henze T (Hrsg.) (2005) Symptomatische Therapie der Multiplen Sklerose. Hernan MA, Olek MJ, Ascherio A (2001) Cigarette smoking and incidence of multiple sclerosis. Am J Epidemiol 154(1):69–74.
Hoffmann V, Schimrigk S, Islamova S et al. (2003) Effi cacy and safety of re- peated intrathecal triamcinolone acetonide application in progressive mul-tiple sclerosis patients. J Neurol Sci 211(1–2):81–84.
Hoffmann V, Kuhn W, Schimrigk S et al. (2006) Repeat intrathecal triamci- nolone acetonide application is benefi cial in progressive MS patients. Eur J Neurol 13(1):72–76. Hohlfeld R, Wekerle H (2001) Immunological update on multiple sclerosis. Hohlfeld R, Wiendl H (2001) The ups and downs of multiple sclerosis thera- Hohlfeld R, Wekerle H (2004) Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines. Proc Natl Acad Sci USA 101 (Suppl. 2):14599–14606. Hohlfeld R, Wekerle H (2005) Drug Insight: using monoclonal antibodies to treat multiple sclerosis. Nat Clin Pract Neurol 1(1):34–44.
Hommes OR, Sorensen PS, Fazekas F et al. (2004) Intravenous immunoglob- ulin in secondary progressive multiple sclerosis: randomised placebo-con-trolled trial. Lancet 364(9440):1149–1156.
Holley J (2003) Astrocyte characterization in the multiple sclerosis glial scar. Neuropathol Appl Neurobiol 29(5):434–444.
Hoult JR (1986) Pharmacological and biochemical actions of sulfasalazine. Houzen H, Niino M, Kikuchi S et al. (2003) The prevalence and clinical char- acteristics of MS in northern Japan. J Neurol Sci 211(1–2):49–53.
Howard R, Wiles C, Hirsch N et al. (1992) Respiratory inveolvement in mul- Howard LM, Kohm AP, Castaneda CL et al. (2005) Therapeutic blockade of TCR signal transduction and co-stimulation in autoimmune disease. Curr Drug Targets Infl amm Allergy 4:205–216.
20 Literatur
Howell MD, Winters ST, Olee T et al. (1989) Vaccination against experimen- tal allergic encephalomyelitis with T cell receptor peptides. Science 246:668–670. Hu W, Metselaar J, Cravens PD et al. (2009) PEG minocycline-liposomes ameliorate CNS autoimmune disease. PLoS ONE 4:e4151.
Hume AL, Waxman SG (1988) Evoked potentials in suspected multiple scle- rosis: diagnostic value and prediction of clinical course. J Neurol Sci 83(2–3):191–210.
The IFNB Multiple Sclerosis Study Group and The University of British Co- lumbia MS/MRI Analysis Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43(4):655–661. The IFNB Multiple Sclerosis Study Group and The University of British Co- lumbia MS/MRI Analysis Group (1995) Interferon beta-1b in the treatment of multiple sclerosis: fi nal outcome of the randomized controlled trial. Neu-rology 45(7):1277–1285.
Imamura K, Suzumura A, Hayashi F et al. (1993) Cytokine production by peripheral blood monocytes/macrophages in multiple sclerosis patients. Acta Neurol Scand 87:281–285.
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) (2006) Methoden, Version 2.0 vom 19.12.2006 (www.iqwig.de).
Irvine KA, Blakemore WF (2008) Remyelination protects axons from demy- elination-associated axon degeneration. Brain 131(Pt 6):1464–1477.
Jacobs L, Salazar AM, Herndon R et al. (1987) Intrathecally administered natural human fi broblast interferon reduces exacerbations of multiple scle-rosis. Results of a multicenter, double- blind study. Arch Neurol 44(6):589–595.
Jacobs L, Johnson KP (1994) A brief history of the use of interferons as treat- ment of multiple sclerosis. Arch Neurol 51(12):1245–1252.
Jacobs LD, Cookfair DL, Rudick RA et al. (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 39(3):285–294.
Jacobs LD, Beck RW, Simon JH et al. (2000) Intramuscular interferon beta-1a therapy initiated during a fi rst demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 343(13):898–904.
Jacobsen M, Cepok S, Quak E (2002) Oligoclonal expansion of memory CD8+ T cells in cerebrospinal fl uid from multiple sclerosis patients. Brain 125(Pt 3):538–550.
Jarius S (2007) NMO-IgG in the diagnosis of neuromyelitis optica 68:1076.
Jarius S, Wildemann B (2007) Neuromyelitis optica. Der Nervenarzt Jarius S, Paul F, Franciotta D et al. (2008) Mechanisms of Disease: aqua- porin-4 antibodies in neuromyelitis optica. Nat Clin Pract Neurol 4(4):202–214.
Jeffery A, Buncic J (1996) Pediatric Devic’s neuromyelitis optica. J Pediatr Literatur 21
Jiang H, Kashleva H, Xu LX et al. (1998) T cell vaccination induces T cell receptor Vbeta-specifi c Qa-1-restricted regulatory CD8(+) T cells. Proc Natl Acad Sci USA 95:4533–4537.
Jilek S, Schluep M, Meylan P et al. (2008) Strong EBV-specifi c CD8+ T-cell response in patients with early multiple sclerosis. Brain 131(Pt 7):1712–1721.
Johnson KP, Brooks BR, Cohen JA et al. (1995) Copolymer 1 reduces relapse rate and improves disability in relapsing- remitting multiple sclerosis: re-sults of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 45(7):1268–1276.
Johnson KP, Brooks BR, Cohen JA et al.; Copolymer 1 Multiple Sclerosis Study Group (1998) Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neu-rology 50(3):701–708.
Johnson KP, Brooks BR, Ford CC et al. (2000) Sustained clinical benefi ts of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group. Mult Scler 6(4):255–266.
Jonsson S, Andersson G, Fex T et al. (2004) Synthesis and biological evalua- tion of new 1,2-dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for treatment of autoimmune disorders: structure-activity relationship. J Med Chem 47:2075–2088.
Jung JS, Bhat RV, Preston GM et al. (1994) Molecular characterization of an aquaporin cDNA from brain: candidate osmoreceptor and regulator of water balance. Proc Natl Acad Sci USA 91(26):13052–13056.
Jung S, Zielasek J, Kollner G et al. (1996) Preventive but not therapeutic ap- plication of Rolipram ameliorates experimental autoimmune encephalomy-elitis in Lewis rats. J Neuroimmunol 68(1–2):1–11.
Kaiser H, Kley HH (1992) Kortisontherapie. Stuttgart, New York: Thieme.
Kaiser CC, Shukla DK, Stebbins GT et al. (2009) A pilot test of pioglitazone as an add-on in patients with relapsing remitting multiple sclerosis. J Neu-roimmunol 211:124–130.
Kalkers NF, Barkhof F, Bergers E et al. (2002) The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study. Mult Scler 8:532–533. Kallmann BA, Fackelmann S, Toyka KV et al. (2006) Early abnormalities of evoked potentials and future disability in patients with multiple sclerosis. Mult Scler 12(1):58–65.
Kantarci O, Siva A, Eraksoy M et al. (1998) Survival and predictors of disabil- ity in Turkish MS patients. Turkish Multiple Sclerosis Study Group (TUMSSG). Neurology 51(3):765–772. Kantarci O, Weinshenker BG (2005) Natural history of multiple sclerosis. Kantarci O, Wingerchuk D (2006) Epidemiology and natural history of mul- tiple sclerosis: new insights. Curr Opin Neurol 19(3):248–254.
22 Literatur
Kappos L, Patzold U, Dommasch D et al. (1988) Cyclosporine versus aza- thioprine in the long-term treatment of multiple sclerosis – results of the German multicenter study. Ann Neurol 23(1):56–63.
Kappos L (1990) Immunosuppressive therapy of multiple sclerosis using cyclosporin A and azathioprine. Long-term effects, risks, proton spin tomo-graphy and immunological fi ndings. Schriftenr Neurol 32:1–200. Kappos L, Radü EW, Bernasconi L et al. (1993) Treatment of multiple sclero- sis with 15 +/- deoxyspergualin. Design of a controlled study with close MRI-monitoring. Schweiz Arch Neurol Psychiatr 144(3):198–201.
Kappos L, Radü EW, Haas J et al.; DSG Study Group (1995) Deoxsyspergua- line in MS: a second interim analysis of the European multicentre study. J Neurol 241(Suppl. 2):S27.
Kappos L, Radu EW, Dellas S et al. (1996) Deoxyspergualine in the treatment of active MS: fi nal analysis of the European multicenter study. Neurology 46(Suppl. 2):A410–411.
Kappos L (1999) Multiple sclerosis trials. Lancet 353(9171):2242–2243.
Kappos L, Comi G, Panitch H et al. (2000) Induction of a non-encephalito- genic type 2 T-helper cell autoimmune response in multiple Sclerosis after administration of an altered peptide ligand in a placebo controlled, rand-omized phase II trial. Nat Med 6(10):1176–1182.
Kappos L, Polman C, Pozzilli C et al. (2001) Final analysis of the European multicenter trial on IFNbeta-1b in secondary-progressive MS. Neurology 57(11):1969–1975.
Kappos L, Clanet M, Sandberg-Wollheim M et al.; European Interferon Beta- 1a IM Dose-Comparison Study Investigators (2005) Neutralizing antibod-ies and effi cacy of interferon beta-1a: a 4-year controlled study. Neurology 65(1):40–47.
Kappos L, Antel J, Comi G et al.; FTY720 D2201 Study Group (2006a) Oral fi ngolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 355(11):1124–1140.
Kappos L, Polman CH, Freedman MS et al. (2006b) Treatment with inter- feron beta-1b delays conversion to clinically defi nite and McDonald MS in patients with clinically isolated syndromes. Neurology 67(7):1242–1249. Kappos L, Miller DH, MacManus DG et al. (2006c) Effi cacy of a novel oral single-agent fumarate, BG00012, in patients with relapsing-remitting mul-tiple sclerosis: results of a phase 2 study. J Neurol 253:27. Kappos L, Gold R, Miller DH et al.; BG-12 Phase IIb Study Investigators (2008) Effi cacy and safety of oral fumarate in patients with relapsing-re-mitting multiple sclerosis: a multicentre, randomised, double-blind, place-bo-controlled phase IIb study. Lancet 372:1463–1472.
Kappos L, Barkhof F, Comi G et al. (2010) A placebo-controlled trial of oral fi ngolimod in relapsing multiple sclerosis. N Engl J Med (Epub ahead of print).
Karussis DM, Lehmann D, Slavin S et al. (1993a) Inhibition of acute, experi- mental autoimmune encephalomyelitis by the synthetic immunomodulator Linomide. Ann Neurol 34:654–660.
Karussis DM, Lehmann D, Slavin S et al. (1993b) Treatment of chronic relaps- ing experimental autoimmune encephalomyelitis with the synthetic immu- Literatur 23
nomodulator Linomide (quinoline-3-carboxamide). Proc Natl Acad Sci USA 90:6400–6404.
Karussis DM, Meiner Z, Lehmann D et al. (1996) Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: a dou-ble blind, placebo-controlled pilot study with monthly magnetic resonance imaging evaluation. Neurology 47:341–346.
Kassiotis G, Kollias G (2001) Uncoupling the proinfl ammatory from the im- munosuppressive properties of tumor necrosis factor (TNF) at the p55 TNF receptor level: implications for pathogenesis and therapy of autoimmune demyelination. J Exp Med 193(4):427–434.
Kastrup O, Stude P, Limmroth V (2002) Balo’s concentric sclerosis: evolution of active demyelination demonstrated by serial contrast–enhanced MRI. J Neurol 249:811–814.
Kawai T, Andrews D, Colvin RB et al. (2000) Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med 6:114.
Kazatchkine MD, Kaveri SV (2001) Immunomodulation of autoimmune and infl ammatory diseases with intravenous immune globulin. N Engl J Med 345(10):747–755. Keegan M, Pineda AA, McClelland RL et al. (2002) Plasma exchange for se- vere attacks of CNS demyelination: Predictors of response. Neurology 58(1):143–146.
Keegan M, Konig F, McClelland R et al. (2005) Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plas-ma exchange. Lancet 366:579–582.
Keeley KA, Rivey MP, Allington DR (2005) Natalizumab for the treatment of multiple sclerosis and Crohn’s disease. Ann Pharmacother 39:1833–1843.
Kersting W (2002) Gerechtigkeitsethische Überlegungen zur Gesundheits- versorgung. In: Schöffski O, Graf v.d. Schulenburg J-M. (Hrsg.) Gesundhei-tsökonomische Evaluationen. Berlin: Springer. S. 25–49.
Kerschensteiner M, Gallmeier E, Behrens L et al. (1999) Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in infl ammatory brain lesions: a neuroprotective role of infl am-mation? J Exp Med 189(5):865–870. Kerschensteiner M, Stadelmann C, Dechant G et al. (2003) Neurotrophic cross-talk between the nervous and immune systems: implications for neu-rological diseases. Ann Neurol 53:292–304. Khalili K, White MK (2006) Human demyelinating disease and the polyoma- virus JCV. Mult Scler 12(2):133–142.
Khan O, Tselis AC, Kamholz JA et al. (2001) A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis: results after 18 months of therapy. Mult Scler 7(6):349–353.
Khan O, Shen Y, Caon C et al. (2005) Axonal metabolic recovery and poten- tial neuroprotective effect of glatiramer acetate in relapsing-remitting mul-tiple sclerosis. Mult Scler 11(6):646–651.
24 Literatur
Khatri BO, McQuillen MP, Harrington GJ et al. (1985) Plasmapheresis in progressive MS. Neurology 35(4):614.
Khurana DS, Melvin JJ, Kothare SV et al. (2005) Acute disseminated en- cephalomyelitis in children: discordant neurologic and neuroimaging ab-normalities and response to plasmapheresis. Pediatrics 116:431–436.
Kieseier BC, Kiefer R, Wells G et al. (1998) Matrix metalloproteinases-9 and -7 are regulated in experimental autoimmune encephalomyelitis. Brain 121:159–166.
Kieseier BC, Wiendl H (2007) Oral Disease-modifying treatments for multiple sclerosis: the story so far. CNS Drugs 21(6):483–502. Killestein J, Olsson T, Wallstrom E et al. (2002) Antibody-mediated suppres- sion of Vbeta5.2/5.3(+) T cells in multiple sclerosis: results from an MRI-monitored phase II clinical trial. Ann Neurol 51:467–474.
Kinkel RP, Kollman C, O’Connor P et al.; CHAMPIONS Study Group (2006) IM interferon beta-1a delays defi nite multiple sclerosis 5 years after a fi rst demyelinating event. Neurology 66(5):678–684. Kira J (2003) Multiple sclerosis in the Japanese population. Lancet Neurol Kita M, Goodkin DE, Bacchetti P et al. (2000) Magnetization transfer ratio in new MS lesions before and during therapy with IFNbeta-1a. Neurology 54(9):1741–1745. Kleinschmidt-DeMasters BK, Tyler KL (2005) Progressive multifocal leukoen- cephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 353:369–374.
Kleinschnitz C, Schroeter M, Jander S et al. (2004) Induction of granulocyte colony-stimulating factor mRNA by focal cerebral ischemia and cortical spreading depression. Brain Res Mol Brain Res 131:73–78. Kleinschnitz C, Meuth SG, Kieseier BC et al. (2007) Immunotherapeutic Ap- proaches in MS: Update on Pathophysiology and Emerging Agents or Strat-egies. EMID-DT 7(1):35–63. Klinkert WEF, Kojima K, Lesslauer W et al. (1997) TNF-alpha receptor fusion protein prevents experimental auto-immune encephalomyelitis and demy-elination in Lewis rats: an overview. J Neuroimmunol 72:163–168.
Klotz L, Schmidt M, Giese T et al. (2005) Proinfl ammatory stimulation and pioglitazone treatment regulate peroxisome proliferator-activated receptor gamma levels in peripheral blood mononuclear cells from healthy controls and multiple sclerosis patients. J Immunol 175:4948–4955.
Kobata T, Azuma M, Yagita H et al. (2000) Role of costimulatory molecules in autoimmunity. Rev Immunogenet 2(1):74–80. Kobelt G, Lindgren P, Parkin D. et al. (2000) Cost and quality of life in mul- tiple sclerosis: a cross-sectional observational study in Germany. 2000SSE/EFI working paper series in Economics and Finance, nr 399.
Kobelt G, Lindgren P, Smala A et al. (2001). Costs and Quality of Life in Multiple Sclerosis. An observational study in Germany. Health Economics in Prevention and Care 2:60–68.
Kobelt G, Berg J, Lindgren P et al. (2006) Costs and quality of life of multiple sclerosis in Germany. Eur J Health Econ 7:S34–S44. Literatur 25
Koch-Henriksen N, Sorensen PS, Christensen T et al.; Danish Multiple Scle- rosis Group (2006) A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis. Neurology 66(7):1056–1060. Kohm AP, Williams JS, Bickford AL et al. (2005) Treatment with nonmi- togenic anti-CD3 monoclonal antibody induces CD4+ T cell unresponsive-ness and functional reversal of established experimental autoimmune en-cephalomyelitis. J Immunol 174:4525–4534.
König FB, Wildemann B, Nessler S et al. (2008) Persistence of immunopatho- logical and radiological traits in multiple sclerosis. Arch Neurol 65(11):1527–1532. Kopadze T, Dehmel T, Mylius HA et al (2007) Treosulfan impedes the migra- tion of immunocompetent cells. J Neurol 254:1457–1458.
Koralnik IJ (2006) Progressive multifocal leukoencephalopathy revisited: Has the disease outgrown its name? Ann Neurol 60(2):162–173.
Korn T, Magnus T, Toyka K et al. (2004) Modulation of effector cell functions in experimental autoimmune encephalomyelitis by lefl unomide-mechanisms independent of pyrimidine depletion. J Leukoc Biol 76:950–960. Kornek B, Stoch MK, Weissert R et al. (2000) Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of ax-onal injury in active, inactive and remyelinated lesions. Am J Pathol 157(1):267–276.
Kornek B, Storch MK, Bauer J et al. (2001) Distribution of a calcium channel subunit in dystrophic axons in multiple sclerosis and experimental autoim-mune encephalomyelitis. Brain 124:1114–1124. Körner H, Lemckert FA, Chaudhri G et al. (1997) Tumor necrosis factor blockade in actively induced experimental autoimmune encephalomyelitis prevents clinical disease despite activated T cell infi ltration to the central nervous system. Eur J Immunol 27:1973–1981.
Korteweg T, Tintore M, Uitdehaag B et al. (2006) MRI criteria for dissemina- tion in space in patients with clinically isolated syndromes: a multicentre follow-up study. Lancet Neurol 5(3):221–227.
Kraft GH (1999) Rehabilitation still the only way to improve function in multiple sclerosis. Lancet 354(9195):2016–2017.
Krammer PH (2000) CD95’s deadly mission in the immune system. Nature Krapf H, Morrissey SP, Zenker O et al.; MIMS Study Group (2005) Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial. Neu-rology 65(5):690–695.
Kremenchutzky M, Rice GP, Baskerville J et al. (2006) The natural history of multiple sclerosis: a geographically based study 9: observations on the pro-gressive phase of the disease. Brain 129(Pt 3):584–594. Krishnamoorthy G, Lassmann H, Wekerle H et al. (2006) Spontaneous opti- cospinal encephalomyelitis in a double-transgenic mouse model of autoim-mune T cell/B cell cooperation. J Clin Invest 116(9):2385–2392.
Kroner A, Mehling M, Hemmer B et al. (2005) A PD-1 polymorphism is as- sociated with disease progression in multiple sclerosis. Ann Neurol 58(1):50–57.
26 Literatur
Krupp LB, Coyle PK, Doscher C et al. (1995) Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amanta-dine, pemoline, and placebo. Neurology 45(11):1956–1961. Krupp LB, Christodoulou C, Melville P et al. (2004) Donepezil improved memory in multiple sclerosis in a randomized clinical trial. Neurology 63:1579–1585.
Krupp L, Banwell B, Tenenbaum S et al. for the International Pediatric MS Study Group (2007) Consensus defi nitions proposed for pediatric multiple sclerosis. Neurology 68:S7–S12.
Kuhle J, Pohl C, Mehling M et al. (2007) Lack of association between antimy- elin antibodies and progression to multiple sclerosis. N Engl J Med 356(4):371–378.
Kuhlmann T, Lingfeld G, Bitsch A (2002) Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain 125(Pt 10):2202–2212.
Kuokkanen S, Gschwend M, Rioux JD et al. (1997) Genomewide scan of multiple sclerosis in Finnish multiplex families. Am J Hum Genet 61(6):1379–1387.
Kurtzke JF (1980) Epidemiologic contributions to multiple sclerosis: an over- Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an ex- panded disability status scale (EDSS). Neurology 33(11):1444–1452.
Kurtzke JF (1991). Multipe sclerosis: changing times. Neuroepidemiology Kurtzke JF, Heltberg A (2001) Multiple sclerosis in the Faroer Islands: an epitome. J Clin Epidemiol 54(1):1–22.
Kutzelnigg A, Lucchinetti CF, Stadelmann C et al. (2005) Cortical demyelina- tion and diffuse white matter injury in multiple sclerosis. Brain 128:2705–2712.
Kutzelnigg A, Faber-Rod JC, Bauer J et al. (2007) Widespread demyelination in the cerebellar cortex in multiple sclerosis. Brain Pathol 17(1):38–44.
Kwak B, Mulhaupt F, Myit S et al. (2000) Statins as a newly recognized type of immunomodulator. Nat Med 6:1399–1402. Lalive P, Menge T, Barman I et al. (2006) Identifi cation of new serum autoan- tibodies in neuromyelitis optica using protein microarrays. Neurology 67(1):176–177.
Lampasona V, Franciotta D, Furlan R et al. (2004) Similar low frequency of anti-MOG IgG and IgM in MS patients and healthy subjects. Neurology 62(11):2092–2094.
Lang HL, Jacobsen H, Ikemizu S et al. (2002) A functional and structural basis of TCR cross-reactivity in multiple sclerosis. Nat Immunol 3(10):940–943.
Langer-Gould A, Huang SM, Gupta R et al. (2009) Exclusive Breastfeeding and the Risk of Postpartum Relapses in Women With Multiple Sclerosis. Arch Neurol 66(8):958–963.
Lappe-Siefke C, Goebbels S, Gravel M et al. (2003) Disruption of Cnp1 un- couples oligodendroglial functions in axonal support and myelination. Nat Genet 33(3):366–374.
Literatur 27
Lassmann H (1998) Neuropathology in multiple sclerosis: new concepts. Mult Lassmann H, Bruck W, Lucchinetti C (2001) Heterogeneity of multiple scle- rosis pathogenesis: implications for diagnosis and therapy. Trends Mol Med 7(3):115–121.
Lau K, Wong L, Li L et al. (2002) Epidemiological study of multiple sclerosis in Hong Kong Chinese: questionnaire survey. Hong Kong Med J 8:77.
Leake JA, Albani S, Kao AS et al. (2004) Acute disseminated encephalomyeli- tis in childhood: epidemiologic, clinical and laboratory features. Pediatr Infect Dis J 23:756–764.
Leary SM, Thompson AJ (2005) Primary progressive multiple sclerosis: cur- rent and future treatment options. CNS Drugs 19(5):369–376.
Lebwohl M, Tyring SK, Hamilton TK et al. (2003) A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 349:2004–2013. Lee KH, Hashimoto SA, Hooge JP et al. (1991) Magnetic resonance imaging of the head in the diagnosis of multiple sclerosis: a prospective 2-year fol-low-up with comparison of clinical evaluation, evoked potentials, oligo-clonal banding, and CT. Neurology 41(5):657–660.
Lehmann HC, Hartung HP, Hetzel GR et al. (2006) Plasma exchange in neu- roimmunological disorders: Part 1: Rationale and treatment of infl amma-tory central nervous system disorders. Arch Neurol 63(7):930–935. Lennon VA, Wingerchuk DM, Kryzer TJ et al. (2004) A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364(9451):2106–2112.
Lennon V, Kryzer TJ, Pittock SJ et al. (2005) IgG marker of optic-spinal mul- tiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 202(4):473–477. Lennon VA, Kryzer TJ, Pittock SJ et al. (2005) IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 202:473–477.
Leocani L, Rovaris M, Boneschi FM et al. (2006) Multimodal evoked poten- tials to assess the evolution of multiple sclerosis: a longitudinal study. J Neurol Neurosurg Psychiatry 77(9):1030–1035.
Le Page E, Leray E, Taurin G et al. (2008) Mitoxantrone as induction treat- ment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive pa-tients. J Neurol Neurosurg Psychiatry 79:52–56.
Leussink IV, Lehmann HC, Meyer zu Hörste G et al. (2008) Rituximab in- duces clinical stabilization in a patient with fulminant multiple sclerosis not responding to natalizumab – evidence for disease heterogeneity. J Neurol 255:1436–1438.
Levin LI, Munger KL, Rubertone MV et al. (2005) Temporal relationship between elevation of Epstein-Barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis. JAMA 293(20):2496–2500.
Li DK, Zhao GJ, Paty DW (2001) Randomized controlled trial of interferon- beta-1a in secondary progressive MS: MRI results. Neurology 56(11):1505–1513.
28 Literatur
Li W, Maeda Y, Yuan RR et al. (2004) Benefi cial effect of erythropoietin on experimental allergic encephalomyelitis. Ann Neurol 56:767–777. Lincoln MR, Montpetit A, Cader MZ et al. (2005) A predominant role for the HLA class II region in the association of the MHC region with multiple sclerosis. Nat Genet 37(10):1108–1112.
Lindsey JW, Hodgkinson S, Mehta R et al. (1994) Repeated treatment with chimeric anti-CD4 antibody in multiple sclerosis. Ann Neurol 36:183–189.
Link H, Möller E, Muller R et al. (1977) Immunoglobulin abnormalities in spinal fl uid in multiple sclerosis. Acta Neurol Scand 63(Suppl.):173–191. Linker RA, Kieseier BC, Gold R (2008a) Identifi cation and development of new therapeutics for multiple sclerosis. Trends Pharmacol Sci 29:558–565.
Linker RA, Lee DH, Stangel M et al. (2008b) Fumarates for the treatment of multiple sclerosis: potential mechanisms of action and clinical studies. Ex-pert Rev Neurother 2008;8:1683–90 Linsley PS, Brady W, Urnes M et al. (1991) CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 174:561–569. Liu J, Marino MW, Wong G et al. (1998) TNF is a potent anti-infl ammatory cytokine in autoimmune-mediated demyelination. Nat Med 4:78–83.
Lo AC, Saab CY, Black JA et al. (2003) Phenytoin protects spinal cord axons and preserves axonal conduction and neurological function in a model of neuroinfl ammation in vivo. J Neurophysiol 90:3566–3571.
Lolli F, Mulinacci B, Carotenuto A et al. (2005) An N-glucosylated peptide detecting disease-specifi c autoantibodies, biomarkers of multiple sclerosis. Proc Natl Acad Sci USA 102(29):10273–10278. Lovett-Racke AE, Bittner P, Cross AH et al. (1998) Regulation of experimen- tal autoimmune encephalomyelitis with insulin-like growth factor (IGF-1) and IGF-1/IGF-binding protein-3 complex (IGF-1/IGFBP3). J Clin Invest 101:1797–1804. Lublin F, Reingold SC (1996) Defi ning the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46(4):907–911.
Lublin F (1999) A phase II trial of anti-CD11/CD18 monoclonal antibody in acute exacerbations of MS. Neurology 52(Suppl. 2).
Lublin F, Cutter G, Elfont R et al. (2001) A trial to assess the safety of combin- ing therapy of interferon beta 1a and glatiramer acetate in patients with relapsing MS. Neurology 56(Suppl. 3): A 148.
Lucchinetti C, Brück W, Rodriguez M et al. (1996) Distinct patterns of mul- tiple sclerosis pathology indicates heterogeneity on pathogenesis. Brain Pathol 6(3):259–274.
Lucchinetti C, Brück W, Parisi J et al. (2000) Heterogeneity of multiple scle- rosis lesions: implications for the pathogenesis of demyelination. Ann Neu-rol 47(6):691–693.
Lucchinetti C, Mandler RN, McGavern D et al. (2002) A role for humoral mechanisms in the pathogenesis of Devic’s neuromyelitis optica. Brain 125:1450–1461.
Literatur 29
Lucchinetti C, Parisi J, Bruck W (2005) The pathology of multiple sclerosis. Ludwin SK (2000). The neuropathology of multiple sclerosis. Neuroimaging Lunemann JD, Edwards N, Muraro PA et al. (2006) Increased frequency and broadened specifi city of latent EBV nuclear antigen-1-specifi c T cells in multiple sclerosis. Brain 129(Pt 6):1493–1506. Lycklama G (2000) Spinal cord magnetic resonance imaging in suspected mul- tiple sclerosis. Eur Radiol 10(2):368–376.
Mackin GA, Dawson DM, Hafl er DA et al. (1992) Treatment of Multiple Sclerosis with cyclophosphamide. In: Rudick RA, Goodkin DE (Hrsg.) Treatment of Multiple Sclerosis – Trial Design, Results and Future Perspec-tives. London: Springer. S. 199–216.
Madsen LS, Andersson EC, Jansson L et al. (1999) A humanized model for multiple sclerosis using HLA-DR2 and a human T-cell receptor. Nat Genet 23(3):343–347.
Maeda A, Sobel RA (1996) Matrix metalloproteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions. J Neuropathol Exp Neurol 55:300–309.
Magnus T, Schreiner B, Korn T et al. (2005) Microglial expression of the B7 family member B7 homolog 1 confers strong immune inhibition: implica-tions for immune responses and autoimmunity in the CNS. J Neurosci 25(10):2537–2546.
Mancardi GL, Sardanelli F, Parodi RC et al. (1998) Effect of copolymer-1 on serial gadolinium-enhanced MRI in relapsing remitting multiple sclerosis. Neurology 50(4):1127–1133.
Mancardi GL, Saccardi R, Filippi M et al. (2001) Autologous hematopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MS. Neurology 57:62–68.
Mandala S, Hajdu R, Bergstrom J et al. (2002) Alteration of lymphocyte traf- fi cking by sphingosine-1-phosphate receptor agonists. Science 296:346–349.
Mandler R, Ahmed W, Dencoff JE. (1998) Devic’s neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathio-prine. Neurology 51(4):1219–1920.
Manley G, Fujimura M, Ma T et al. (2000) Aquaporin-4 deletion in mice re- duces brain edema after acute water intoxication and ischemic stroke. Nat Med 6(2):159–163.
Marecki S, Kirkpatrick P (2004) Efalizumab. Nat Rev Drug Discov 3:473– Markovic-Plese S, Bielekova B, Kadom N et al. (2003) Longitudinal MRI study: the effects of azathioprine in MS patients refractory to interferon beta-1b. Neurology 60(11):1849–1851.
Marracci GH, McKeon GP, Marquardt WE et al. (2004) Alpha lipoic acid inhibits human T-cell migration: implications for multiple sclerosis. J Neu-rosci Res 78:362–370. Martin R, McFarland HF, McFarlin DE (1992) Immunological aspects of demyelinating diseases. Annu Rev Immunol 10:153–187.
30 Literatur
Massacesi L, Parigi A, Barilaro A et al. (2005) Effi cacy of azathioprine on multiple sclerosis new brain lesions evaluated using magnetic resonance imaging. Arch Neurol 62(12):1843–1847.
Mathey E, Breithaupt C, Schubart AS et al. (2004) Sorting the wheat form the chaff: identifying demyelinating components of the myelin-oligodendrocyte-glycoprotein (MOG)-specifi c autoantibody repertoire. Eur J Immunol 34(8):2065–2071.
Matiello M, Lennon VA, Jacob A et al. (2008) NMO-IgG predicts the outcome of recurrent optic neuritis. Neurol 70(23):2197–2000.
Matloubian M, Lo CG, Cinamon G et al. (2004) Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 427:355–360.
Matthews PM, Wattam-Bell JRB, Pountey E (1982) Evoked potentials in the diagnosis of multiple sclerosis: a follow-up study. J Neurol Neurosurg Psy-chiatry 45:303–307. Mäurer, M., Rieckmann, P (2000) Relapsing-remitting multiple sclerosis: What is the potential for combination therapy? BioDrugs 13:149–158.
Mäurer M, Gold R, Toyka KV et al. (2001) Behandlung der schubförmigen Multiplen Sklerose mit rekombinanten Interferon-β-Präparaten: Aspekte zur Pharmakologie und Dosierung. Nervenarzt 72(2):108–116.
Mayr WT, Pittock SJ, McClelland RL et al. (2003) Incidence and prevalence of multiple sclerosis in Olmsted County, Minnesota, 1985–2000. Neurol-ogy 61(10):1373–1377.
McDonald WI, Compston A, Edan G et al. (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50(1):121–127.
McFarland HF, Barkhof F, Antel J et al. (2002) The role of MRI as a surrogate outcome measure in multiple sclerosis. Mult Scler 8(1):40–51.
McLean MA, Luxton RW, Thompson A (1990) A study of immunoglobulin G in the cerebrospinal fl uid of 10007 patients with suspected neurological disease using isoelectric focusing and the lg IgG-index. Brain 113:1269–1289.
McLeod JG, Hammond SR, Hallpike JF (1994) Epidemiology of multiple sclerosis in Australia. With NSW and SA survey results. Med J Aust 160(3):117–122.
McKeon A, Lennon VA, Lotze T et al. (2008) CNS aquaporin-4 autoimmu- Medaer R, Stinissen P, Truyen L et al. (1995) Depletion of myelin-basic-protein autoreactive T cells by T-cell vaccination: pilot trial in multiple sclerosis. Lancet 346(8978):807–808.
Medana I, Martinic MA, Wekerle H et al. (2001) Transection of major histo- compatibility complex class I-induced neurites by cytotoxic T lymphocytes. Am J Pathol 159(3):809–815.
Medana IM, Esiri MM (2003) Axonal damage: a key predictor of outcome in human CNS diseases. Brain 126(Pt 3):515–530. Meinl E, Weber F, Drexler K et al. (1993) Myelin basic protein-specifi c T lymphocyte repertoire in multiple sclerosis. Complexity of the response and Literatur 31
dominance of nested epitopes due to recruitment of multiple T cell clones. J Clin Invest 92:2633–2643.
Meinl E (1999) Concepts of viral pathogenesis of multiple sclerosis. Curr Opin Meinl E, Krumbholz M, Hohlfeld R (2006) B lineage cells in the infl amma- tory central nervous system environment: migration, maintenance, local antibody production, and therapeutic modulation Ann Neurol 59(6):880–892.
Melamud L, Madalena L, Facio ML, et al. (2006) Cerebrospinal fl uid fi ndings in Devic’s neuromyelitis optica. Mult Scler 12:S61. Menge T, Hemmer B, Nessler S et al. (2005) Acute disseminated encephalo- myelitis: an update. Arch Neurol 62:1673–1680.
Menge T, Lalive PH, von Budingen HC et al. (2005a) Antibody responses against galactocerebroside are potential stage-specifi c biomarkers in multi-ple sclerosis. J Allergy Clin Immunol 116(2):453–459.
Menge T, Kieseier BC, Nessler S et al. (2007) Acute disseminated encephalo- myelitis: an acute hit against the brain. Current Opinion in Neurology 20:247–254.
Menge T, Weber MS, Hemmer B et al. (2008) Disease-modifying agents for multiple sclerosis: recent advances and future prospects. Drugs 68:2445–2468.
Merkler D, Horvath E, Bruck W et al. (2006) ‚Viral deja vu‘ elicits organ- specifi c immune disease independent of reactivity to self. J Clin Invest 116:1254–1263.
Metz LM, Zhang Y, Yeung M et al. (2004) Minocycline reduces gadolinium- enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann Neurol 55:756.
Mikaelo Y, Suissa S, Vallee L et al. (2004) First episode of acute CNS infl am- matory demyelination in childhood: prognostic factors for multiple sclero-sis and disability. J Pediatr 144:246–252.
Mikol DD, Barkhof F, Chang P et al. on behalf of the REGARD study group (2008) Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glati-ramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol 7:903–914.
Millefi orini E, Gasperini C, Pozzilli C et al. (1997) Randomized placebo-con- trolled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J Neurol 244(3):153–159.
Miller AE, Morgante LA, Buchwald LY et al. (1997) A multicenter, ran- domized, double-blind, placebo-controlled trial of infl uenza immunization in multiple sclerosis. Neurology 48(2):312–314.
Miller AE, Spada V, Beerkircher D et al. (2008) Long-term (up to 22 years), open-label, compassionate-use study of glatiramer acetate in relapsing-re-mitting multiple sclerosis. Mult Scler 14:494–499.
Miller D, Barkhof F, Montalban X et al. (2005a) Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diag-nosis, and prognosis. Lancet Neurol 4(5):281–288.
32 Literatur
Miller D, Barkhof F, Montalban X et al. (2005b) Clinically isolated syndromes suggestive of multiple sclerosis, part 2: non-conventional MRI, recovery processes, and management. Lancet Neurol 4(6):341–348. Miller DH, Thompson AJ, Morrissey SP et al. (1992) High dose steroids in acute relapses of multiple sclerosis: MRI evidence for a possible mechanism of therapeutic effect. J Neurol Neurosurg Psychiatry 55(6):450–453.
Miller DH (1996) Guidelines for MRI monitoring of the treatment of multiple sclerosis: recommendations of the US Multiple Sclerosis Society’s task force. Mult Scler 1(6):335–338.
Miller DH, Albert PS, Barkhof F et al. (1996) Guidelines for the use of mag- netic resonance techniques in monitoring the treatment of multiple sclero-sis. US National MS Society Task Force. Ann Neurol 39:6–16.
Miller DH, Khan OA, Sheremata WA et al.; International Natalizumab Mul- tiple Sclerosis Trial Group (2003) A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 348(1):15–23.
Miller DH, Filippi M, Fazekas F et al. (2004) Role of magnetic resonance imaging within diagnostic criteria for multiple sclerosis. Ann Neurol 56(2):273–278.
Miller DM, Weinstock-Guttman B, Bethoux F et al. (2000) A meta-analysis of methylprednisolone in recovery from multiple sclerosis exacerbations. Mult Scler 6(4):267–273.
Milligan NM, Newcombe R, Compston DA (1987) A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects. J Neurol Neurosurg Psychiatry 50(5):511–516.
Miron VE, Hall JA, Kennedy TE et al. (2008a) Cyclical and dose-dependent responses of adult human mature oligodendrocytes to fi ngolimod. Am J Pathol. 2008;173:1143-52.
Miron VE, Jung CG, Kim HJ et al. (2008b) FTY720 modulates human oli- godendrocyte progenitor process extension and survival. Ann Neurol. 2008;63:61-71.
Misu T, Fujihara K, Nakashima I et al. (2005) Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica. Neurology 65:1479.
Misu T, Fujihara K, Kakita A et al. (2007) Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain 130:1224.
Moalem G, Leibowitz-Amit R, Yoles E et al. (1999) Autoimmune T cells protect neurons form secondary degeneration after central nervous system axotomy. Nat Med 5(1):49–55.
Monson NL, Cravens PD, Frohman EM et al. (2005) Effect of rituximab on the peripheral blood and cerebrospinal fl uid B cells in patients with pri-mary progressive multiple sclerosis. Arch Neurol 62:258–264.
Moriabadi NF, Niewiesk S, Kruse N et al. (2001) Infl uenza vaccination in MS: absence of T-cell response against white matter proteins. Neurology 56(7):938–43.
Morini M, Roccatagliata L, Dell’Eva R et al. (2004) Alpha-lipoic acid is effec- tive in prevention and treatment of experimental autoimmune encephalo-myelitis. J Neuroimmunol 148:146–153.
Morrissey SP, Miller DH, Kendall BE et al. (1993) The signifi cance of brain magnetic resonance imaging abnormalities at presentation with clinically Literatur 33
isolated syndromes suggestive of multiple sclerosis. A 5-year follow-up stu-dy. Brain 116(Pt 1):135–146.
Multiple Sclerosis Study Group (MSG) (1990) Effi cacy and toxicity of cy- closporine in chronic progressive multiple sclerosis: a randomized, double-blinded, placebo-controlled clinical trial. The Multiple Sclerosis Study Group. Ann Neurol 27(6):591–605.
Multiple Sklerose Therapie Konsensus Gruppe (MSTKG) (1999) Immunmo- dulierende Stufentherapie der Multiplen Sklerose. Nervenarzt 70(4):371–386.
Multiple Sklerose Therapie Konsensus Gruppe (MSTKG) (2001) Immunmo- dulierende Stufentherapie der Multiplen Sklerose. 1. Ergänzung. Nervenarzt 72(2):150–157.
Multiple Sklerose Therapie Konsensus Gruppe (MSTKG) (2002) Immunmo- dulierende Stufentherapie der Multiplen Sklerose. 2. Ergänzung. Der Ner-venarzt 73(6):556–563.
Multiple Sklerose Therapie Konsensus Gruppe (MSTKG) (2006) Immunmo- dulatorische Stufentherapie der Multiplen Sklerose. Aktuelle Therapieem-pfehlungen. Nervenarzt 77(12):1506–1518. Multiple Sklerose Therapie Konsensus Gruppe (MSTKG) (2008) Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. J Neurol 255(10):1449–1463.
Muller H, Hofer S, Kaneider N et al. (2005) The immunomodulator FTY720 interferes with effector functions of human monocyte-derived dendritic cells. Eur J Immunol 35:533–545.
Munger KL, Zhang SM, O’Reilly E et al. (2004) Vitamin D intake and inci- dence of multiple sclerosis. Neurology 62(1):60–65.
Munger KL, Levin LI, Hollis BW et al. (2006) Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 296(23):2832–2838.
Muraro PA, Douek DC, Packer A et al. (2005) Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. J Exp Med 01:805–816.
Murphy N, Confavreux C, Haas J (1998a) Quality of life in multiple sclerosis in France, Germany, and in the United Kingdom. J Neurol Neurosurg Psy-chiatry 65:460–466.
Murphy N, Confavreux C, Haas J et al. (1998b). Economic evaluation of multiple sclerosis in the UK, Germany and France. Pharmacoeconomics 13(5 Pt 2):607–622. Nakashima I, Fujihara K, Miyazawa I et al. (2006) Clinical and MRI features of Japanese patients with multiple sclerosis positive for NMO-IgG. J Neu-rol Neurosurg Psychiatry 77(9):1073–1075. Narayanan S, De Stefano N, Francis GS et al. (2001) Axonal metabolic recov- ery in multiple sclerosis patients treated with interferon beta-1b. J Neurol 248(11):979–986.
NASA MS Cooling Study Group (2003) A randomized controlled study of the acute and chronic effects of cooling therapy for MS. Neurology 60:1955–1960.
34 Literatur
Nash RA, Bowen JD, McSweeney PA et al. (2003) High-dose immunosuppres- sive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Blood 102:2364–2372.
Nashmi R, Fehlings MG (2001) Mechanisms of axonal dysfunction after spi- nal cord injury: with an emphasis on the role of voltage-gated potassium channels. Brain Res Brain Res Rev 38:165–191.
National Institute for Clinical Excellence (NICE) (2004) Beta interferon and glatirameracetate for the treatment of multiple sclerosis. Technology Ap-praisal Guidance No. 32. January 2002, Review Date November 2004 (www.nice.org.uk).
Neuhaus O, Farina C, Yassouridis A et al. (2000) Multiple sclerosis: com- parison of copolymer-1-reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells. Proc Natl Acad Sci USA 97(13):7452–7457.
Neuhaus O, Farina C, Wekerle H et al. (2001) Mechanisms of action of glat- iramer acetate in multiple sclerosis. Neurology 56(6):702–708.
Neuhaus O, Strasser-Fuchs S, Fazekas F et al. (2002) Statins as immunomod- ulators: comparison with interferon-beta 1b in MS. Neurology 59:990–997.
Neumann E, Lechner S, Tarner IH et al. (2003) Evaluation of differentially expressed genes by a combination of cDNA array and RAP-PCR using the AtlasImage 2.0 software. J Autoimmun 21(2):161–166.
Nicholson LB, Greer JM, Sobel RA et al. (1995) An altered peptide ligand mediates immune deviation and prevents autoimmune encephalomyelitis. Immunity 3:397–405.
Nielsen NM, Westergaard T, Rostgaard K et al. (2005) Familial risk of multi- ple sclerosis: a nationwide cohort study. Am J Epidemiol 162(8):774–778.
Niino M, Bodner C, Simard ML et al.(2006) Natalizumab effects on immune cell responses in multiple sclerosis. Ann Neurol 59:748–754. Noseworthy JH, Vandervoort MK, Penman M et al. (1991) Cyclophospha- mide and plasma exchange in multiple sclerosis. Lancet 337(8756):1540–1541.
Noseworthy JH, O’Brien P, Erickson BJ et al. (1998) The Mayo Clinic-Cana- dian Cooperative trial of sulfasalazine in active multiple sclerosis. Neurol-ogy 51(5):1342–1352.
Noseworthy JH, Lucchinetti C, Rodriguez M et al. (2000a) Multiple sclerosis. Noseworthy JH, O’Brien PC, Petterson TM et al. (2000b) IV immunoglobulin does not reverse established weakness in MS: A double-blind, placebo-controlled trial. Neurology 55(8):1135–1143.
Noseworthy JH, Wolinsky JS, Lublin FD et al. (2000c) Linomide in relapsing and secondary progressive MS: part I: trial design and clinical results. North American Linomide Investigators. Neurology 54:1726–1733.
O’Connor P; CHAMPS (2003) The effects of intramuscular interferon beta-Ia in patients at high risk for development of multiple sclerosis: a post hoc analysis of data from CHAMPS. Clin The 25(11):2865–2874.
Literatur 35
O’Connor PW, Goodman A, Willmer-Hulme AJ et al.; Natalizumab Multiple Sclerosis Trial Group (2004) Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects. Neurology 62(11):2038–2043.
O’Connor KC, Appel H, Bregoli L et al. (2005) Antibodies form infl amed central nervous system tissue recognice myelin oligodendrocyte glycopro-tein. J Immunol 175(3):1974–1982.
O’Connor PW, Li D, Freedman MS, Bar-Or A et al.; Terifl unomide Multiple Sclerosis Trial Group; University of British Columbia MS/MRI Research Group (2006a) A Phase II study of the safety and effi cacy of terifl unomide in multiple sclerosis with relapses. Neurology 66(6):894–900.
O’Connor P, Antel J, Comi G (2006b) Oral FTY720 in relapsing MS: Results of the dose-blinded, active drug extension phase of a phase II study. Neurol-ogy 66 (5):A123-A123 Suppl.
O’Connor P, Comi G, Montalban X et al.; FTY720 D2201 Study Group (2009) Oral fi ngolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study. Neurology 72:73–79.
Oksenberg JR, Stuart S, Begovich AB et al. (1990) Limited heterogeneity of rearranged T-cell receptor V alpha transcripts in brains of multiple sclerosis patients. Nature 345(6273):344–346.
Oksenberg JR, Baranzini SE, Barcellos LF et al. (2001) Multiple sclerosis:

Source: http://shop2.kohlhammer.de/shopX/shops/kohlhammer/data/pdf/978-3-17-018463-3_O.pdf

Microsoft word - informatiepakket_inzicht

Informatiepakket InZicht bijgewerkt dd 07-04-2011 Algemeen Algemeen InZicht, Centrum voor Orthopsychiatrie te Nijmegen, behandelt en begeleidt jongeren van 12-21 jaar met een IQ van 70 of hoger, waarbij sprake is van ernstige externaliserende gedragsproblemen én (vermoeden van) psychiatrische problemen (bijv. ADHD, Autisme). Veel van deze jongeren zijn bekend met agressief en (dreigend) crimine

Microsoft word - evaluation of country of origin information report on soma–

REVIEW OF REVISED COI REPORT ON SOMALIA (19 MAY 2010) Judith Gardner Prepared for the for the Advisory Panel on Country Information 3rd September 2010 ACKNOWLEDGEMENTS I am grateful to Dr Laura Hammond and Mark Bradbury for the information they provided. Introduction This is a review of the re-drafted Country of Origin Information Report on Somalia compiled by the Co

© 2010-2017 Pharmacy Pills Pdf